An epidemiological study of neuropathic pain symptoms in Canadian adults

Elizabeth G. VanDenKerkhof (Lead / Corresponding author), Elizabeth G. Mann, Nicola Torrance, Blair H. Smith, Ana Johnson, Ian Gilron

    Research output: Contribution to journalArticle

    19 Citations (Scopus)
    83 Downloads (Pure)

    Abstract

    The reported prevalence of neuropathic pain ranges from 6.9% to 10%; however the only Canadian study reported 17.9%. The objective of this study was to describe the epidemiology of neuropathic pain in Canada. A cross-sectional survey was conducted in a random sample of Canadian adults. The response rate was 21.1% (1504/7134). Likely or possible neuropathic pain was defined using a neuropathic pain-related diagnosis and a positive outcome on the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) or the Douleur Neuropathique 4 (DN4) Questions. The prevalence of likely neuropathic pain was 1.9% (S-LANSS) and 3.4% (DN4) and that of possible neuropathic pain was 5.8% (S-LANSS) and 8.1% (DN4). Neuropathic pain was highest in economically disadvantaged males. There is a significant burden of neuropathic pain in Canada. The low response rate and a slightly older and less educated sample than the Canadian population may have led to an overestimate of neuropathic pain. Population prevalence varies by screening tool used, indicating more work is needed to develop reliable measures. Population level screening targeted towards high risk groups should improve the sensitivity and specificity of screening, while clinical examination of those with positive screening results will further refine the estimate of prevalence.
    Original languageEnglish
    Article number9815750
    Pages (from-to)1-13
    Number of pages13
    JournalPain Research and Management
    Volume2016
    DOIs
    Publication statusPublished - 2016

    Fingerprint

    Neuralgia
    Epidemiologic Studies
    Symptom Assessment
    Self Report
    Signs and Symptoms
    Pain
    Canada
    Population
    Vulnerable Populations
    Epidemiology
    Cross-Sectional Studies
    Sensitivity and Specificity

    Cite this

    VanDenKerkhof, E. G., Mann, E. G., Torrance, N., Smith, B. H., Johnson, A., & Gilron, I. (2016). An epidemiological study of neuropathic pain symptoms in Canadian adults. Pain Research and Management, 2016, 1-13. [9815750]. https://doi.org/10.1155/2016/9815750
    VanDenKerkhof, Elizabeth G. ; Mann, Elizabeth G. ; Torrance, Nicola ; Smith, Blair H. ; Johnson, Ana ; Gilron, Ian. / An epidemiological study of neuropathic pain symptoms in Canadian adults. In: Pain Research and Management. 2016 ; Vol. 2016. pp. 1-13.
    @article{f92c4a3d2c894514a20f32dfe6349c4f,
    title = "An epidemiological study of neuropathic pain symptoms in Canadian adults",
    abstract = "The reported prevalence of neuropathic pain ranges from 6.9{\%} to 10{\%}; however the only Canadian study reported 17.9{\%}. The objective of this study was to describe the epidemiology of neuropathic pain in Canada. A cross-sectional survey was conducted in a random sample of Canadian adults. The response rate was 21.1{\%} (1504/7134). Likely or possible neuropathic pain was defined using a neuropathic pain-related diagnosis and a positive outcome on the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) or the Douleur Neuropathique 4 (DN4) Questions. The prevalence of likely neuropathic pain was 1.9{\%} (S-LANSS) and 3.4{\%} (DN4) and that of possible neuropathic pain was 5.8{\%} (S-LANSS) and 8.1{\%} (DN4). Neuropathic pain was highest in economically disadvantaged males. There is a significant burden of neuropathic pain in Canada. The low response rate and a slightly older and less educated sample than the Canadian population may have led to an overestimate of neuropathic pain. Population prevalence varies by screening tool used, indicating more work is needed to develop reliable measures. Population level screening targeted towards high risk groups should improve the sensitivity and specificity of screening, while clinical examination of those with positive screening results will further refine the estimate of prevalence.",
    author = "VanDenKerkhof, {Elizabeth G.} and Mann, {Elizabeth G.} and Nicola Torrance and Smith, {Blair H.} and Ana Johnson and Ian Gilron",
    note = "This study was funded by the Pfizer Neuropathic Pain Research Award held by Elizabeth G. VanDenKerkhof (https://pfizercns.ca/en/).",
    year = "2016",
    doi = "10.1155/2016/9815750",
    language = "English",
    volume = "2016",
    pages = "1--13",
    journal = "Pain Research and Management",
    issn = "1203-6765",
    publisher = "Pulsus Group",

    }

    VanDenKerkhof, EG, Mann, EG, Torrance, N, Smith, BH, Johnson, A & Gilron, I 2016, 'An epidemiological study of neuropathic pain symptoms in Canadian adults', Pain Research and Management, vol. 2016, 9815750, pp. 1-13. https://doi.org/10.1155/2016/9815750

    An epidemiological study of neuropathic pain symptoms in Canadian adults. / VanDenKerkhof, Elizabeth G. (Lead / Corresponding author); Mann, Elizabeth G.; Torrance, Nicola; Smith, Blair H.; Johnson, Ana; Gilron, Ian.

    In: Pain Research and Management, Vol. 2016, 9815750, 2016, p. 1-13.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - An epidemiological study of neuropathic pain symptoms in Canadian adults

    AU - VanDenKerkhof, Elizabeth G.

    AU - Mann, Elizabeth G.

    AU - Torrance, Nicola

    AU - Smith, Blair H.

    AU - Johnson, Ana

    AU - Gilron, Ian

    N1 - This study was funded by the Pfizer Neuropathic Pain Research Award held by Elizabeth G. VanDenKerkhof (https://pfizercns.ca/en/).

    PY - 2016

    Y1 - 2016

    N2 - The reported prevalence of neuropathic pain ranges from 6.9% to 10%; however the only Canadian study reported 17.9%. The objective of this study was to describe the epidemiology of neuropathic pain in Canada. A cross-sectional survey was conducted in a random sample of Canadian adults. The response rate was 21.1% (1504/7134). Likely or possible neuropathic pain was defined using a neuropathic pain-related diagnosis and a positive outcome on the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) or the Douleur Neuropathique 4 (DN4) Questions. The prevalence of likely neuropathic pain was 1.9% (S-LANSS) and 3.4% (DN4) and that of possible neuropathic pain was 5.8% (S-LANSS) and 8.1% (DN4). Neuropathic pain was highest in economically disadvantaged males. There is a significant burden of neuropathic pain in Canada. The low response rate and a slightly older and less educated sample than the Canadian population may have led to an overestimate of neuropathic pain. Population prevalence varies by screening tool used, indicating more work is needed to develop reliable measures. Population level screening targeted towards high risk groups should improve the sensitivity and specificity of screening, while clinical examination of those with positive screening results will further refine the estimate of prevalence.

    AB - The reported prevalence of neuropathic pain ranges from 6.9% to 10%; however the only Canadian study reported 17.9%. The objective of this study was to describe the epidemiology of neuropathic pain in Canada. A cross-sectional survey was conducted in a random sample of Canadian adults. The response rate was 21.1% (1504/7134). Likely or possible neuropathic pain was defined using a neuropathic pain-related diagnosis and a positive outcome on the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) or the Douleur Neuropathique 4 (DN4) Questions. The prevalence of likely neuropathic pain was 1.9% (S-LANSS) and 3.4% (DN4) and that of possible neuropathic pain was 5.8% (S-LANSS) and 8.1% (DN4). Neuropathic pain was highest in economically disadvantaged males. There is a significant burden of neuropathic pain in Canada. The low response rate and a slightly older and less educated sample than the Canadian population may have led to an overestimate of neuropathic pain. Population prevalence varies by screening tool used, indicating more work is needed to develop reliable measures. Population level screening targeted towards high risk groups should improve the sensitivity and specificity of screening, while clinical examination of those with positive screening results will further refine the estimate of prevalence.

    U2 - 10.1155/2016/9815750

    DO - 10.1155/2016/9815750

    M3 - Article

    VL - 2016

    SP - 1

    EP - 13

    JO - Pain Research and Management

    JF - Pain Research and Management

    SN - 1203-6765

    M1 - 9815750

    ER -